Improving Patients’ Quality of Life After Surgical Treatment of Primary Malignant Bone Tumors Using a Training 3D Model

Authors

  • O. DROBOTUN O.O. Bogomolets NMU, Kyiv, Ukraine
  • V. PROTSENKO SI "Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine" Kyiv, Ukraine
  • N. TERNOVYY R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.04.341

Keywords:

bone tumors, osteosarcoma, chondrosarcoma, treatment, 3D-models, personalized treatment, quality of life

Abstract

Background. Bone neoplasms significantly reduce the patient’s quality of life (QoL) not only during the manifestation of the primary disease but also at various treatment stages. Aim. To study the QoL indicators in patients with primary malignant bone tumors before and after surgical treatment using a training 3D model. Materials and Methods. 44 patients with primary malignant tumors of the lower extremities (osteosarcoma and chondrosarcoma) were treated by surgery. 3D modeling was used to plan the surgical intervention. 3D printing of the models of the pathological foci was performed by the method of layer-by-layer deposition (Fused Deposition Modeling, FDM) using a Creatbot D600 3D printer. The QoL index of patients before and 3 weeks after surgical treatment was measured by the arithmetic sum of the scores of the QLQ-C30 simplified version questionnaire. Results. The surgical removal of a tumor using a training 3D model had a positive effect on the QoL of patients. Before treatment, the QoL index was on average 7.4 ± 1.2 points, and after treatment 9.4 ± 1.3 points, that is, by 27% higher. Conclusions. The use of training 3D models not only implements a strategy of personalized treatment and improves the QoL of patients but also contributes to optimization of the postoperative rehabilitation.

References

Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T. Immunotherapy in soft tissue and bone sarcoma: Unravel- ing the barriers to effectiveness. Theranostics. 2022;12:6106-6129. https://doi.org/10.7150/thno.72800

Mettmann VL, Blattmann C, Friedel G, et al. Primary multi-systemic metastases in osteosarcoma: presentation, treat- ment, and survival of 83 patients of the Cooperative Osteosarcoma Study Group. Cancers (Basel). 2024;16(2):275. https://doi.org/ 10.3390/cancers16020275

Ren J, Zhao C, Sun R, et al. Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. Int J Cancer. 2024;154(9):1626-1638. https://doi.org/10.1002/ijc.34841

Zhu Y, Wu X, Zhang W, Zhang H. Limb-salvage surgery versus extremity amputation for early-stage bone cancer in theextremities: apopulation-basedstudy. Front Surg. 2023;10:1147372. https://doi.org/10.3389/fsurg.2023.1147372

Panez-Toro I, Muñoz-García J, Vargas-Franco JW, et al. Advances in Osteosarcoma. Curr Osteoporos Rep. 2023;21(4):330-343. https://doi.org/10.1007/s11914-023-00803-9.

Leng Y, Li J, Long Z, et al. Osteoblast-derived exosomes promote osteogenic differentiation of osteosarcoma cells via URG4/Wnt signaling pathway. Bone. 2024;178:116933. https://doi.org/10.1016/j.bone.2023.116933

Gerrand C, Athanasou N, Brennan B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7. https://doi.org/10.1186/s13569-016-0047-1

Wang L, Li W, Pan Y. The Eph/Ephrin system in primary bone tumor and bone cancer pain. Aging (Albany NY). 2023;15(14):7324-7332. https://doi.org/10.18632/aging.204852

Zhang Q, Yang Y, You X, et al. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic pat- terns compared with soft tissue sarcomas. Front Oncol. 2023;13:1173275. https://doi.org/10.3389/fonc.2023.1173275

Roberts RD, Lizardo MM, Reed DR, et al. Provocative questions in osteosarcoma basic and translational biology: A report from the Children’s Oncology Group. Cancer. 2019;125:3514-3525. https://doi.org/10.1002/cncr.32351

Salom M, Chiari C, Alessandri JMG, et al. Diagnosis and staging of malignant bone tumours in children: what is due and what is new? J Child Orthop. 2021;15(4):312-321. https://doi.org/10.1302/1863-2548.15.210107

Bartelstein MK, Boland PJ. Fifty years of bone tumors. J Surg Oncol. 2022;126(5):906-912. https://doi.org/10.1002/ jso.27027.

de Ligt KM, Aaronson NK, Liegl G, Nolte S; EORTC Quality of Life Group. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study. Qual Life Res. 2023;32(9):2477-2487. https://doi.org/ 10.1007/s11136-023-03404-2.

Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: A clinical review. J Clin Med. 2023;12(7):2506. https://doi.org/10.3390/jcm12072506

Paulino Pereira NR, Janssen SJ, et al. Physical function and quality of life after resection of mobile spine chondrosar- coma. Global Spine J. 2019;9(7):743-753. https://doi.org/ 10.1177/2192568219830330

Fernando-Canavan L, Abraham P, Devlin N, Tran-Duy A. Health-related quality of life in patients with extremi- ty bone sarcoma after surgical treatment: a systematic review. Qual Life Res. 2024;33(5):1157-1174. https://doi. org/10.1007/s11136-023-03554-3

Downloads

Published

12.12.2024

How to Cite

DROBOTUN, O., PROTSENKO, V., & TERNOVYY, N. (2024). Improving Patients’ Quality of Life After Surgical Treatment of Primary Malignant Bone Tumors Using a Training 3D Model. Experimental Oncology, 46(4), 341–344. https://doi.org/10.15407/exp-oncology.2024.04.341

Issue

Section

Original contributions